Concepedia

Lindsay E. King

LE

Statistics

Publications

11

Citations

464

H-Index

11

Active since

2004

Affiliations

Pfizer (United States)(Current)

Renewable Energy Systems (United States)

Biogen (United States)

Lindsay E. King is an author at Pfizer (United States) specializing in pharmacology, pharmacy, and ligand-binding assays.

Publications per year

2004–2024

11

Publications

11

Ligand Binding Assay Critical Reagents and Their Stability: Recommendations and Best Practices from the Global Bioanalysis Consortium Harmonization Team

Lindsay E. King, Esme Farley, Mami Imazato et al. · The AAPS Journal · 2014 · 71 citations · Full text

, , +16

A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

Divya Mathur, Adam R. Root, Bozena Bugaj‐Gaweda et al. · Clinical Cancer Research · 2020 · 65 citations · Full text

, , +17

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

Alison Betts, Nahor Haddish‐Berhane, John Tolsma et al. · The AAPS Journal · 2016 · 63 citations

, , +17

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

Dhaval K. Shah, Lindsay E. King, Xiaogang Han et al. · The AAPS Journal · 2014 · 60 citations · Full text

, , +17

Detection of aggrecanase- and MMP-generated catabolic neoepitopes in the rat iodoacetate model of cartilage degeneration

Michael J. Janusz, Christopher B. Little, Lindsay E. King et al. · Osteoarthritis and Cartilage · 2004 · 55 citations · Full text

, , +15

1–5 of 11